All In Biotech

Drug Trial Radar · NCT01886378

A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)

An Open-label Phase 2 Study to Assess Safety and Clinical Effects of UX007 in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)

Last checked: Nov 20, 2026Latest source record: Feb 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

29

Actual

Start

Feb 6, 2014

Primary completion

Aug 25, 2016

Study completion Aug 25, 2016

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
First posted
Jun 25, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study was to evaluate the impact of UX007 on acute clinical pathophysiology associated with LC-FAOD following 24 weeks of treatment.

Conditions

  • Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
  • Carnitine Palmitoyltransferase (CPT II) Deficiency
  • Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency
  • Longchain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency
  • Trifunctional Protein (TFP) Deficiency

Interventions

  • UX007Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Time Adjusted-Area Under the Curve (AUC/Time) for Workload During Cycle Ergometry at Week 24Time frame: Baseline, Week 24
  2. Change From Baseline in Time-Adjusted-AUC for Respiratory Exchange Ratio (RER) During Cycle Ergometry at Week 24Time frame: Baseline, Week 24
  3. Change From Baseline in Actual Duration of Exercise During Cycle Ergometry at Week 24Time frame: Baseline, Week 24
  4. Change From Baseline in Distance Traveled During the 12-Minute Walk Test (12MWT) at Week 18Time frame: Baseline (last assessment during the 4-week run-in period), Week 18
  5. Change From Baseline in Energy Expenditure Index (EEI) During the 12MWT at Week 18Time frame: Baseline (last assessment during the 4-week run-in period), Week 18
  6. Change From Baseline in Percentage of the Predicted 6-Minute Walk Test (6MWT) Distance Walked at Week 18Time frame: Baseline (last assessment during the 4-week run-in period), Week 18
  7. Change From Baseline in Physical Summary Score (PHS-10) of the Short Form 10 (SF-10) at Week 24Time frame: Baseline, Week 24
  8. Change From Baseline in Psychosocial Summary Score (PSS-10) of the SF10 at Week 24Time frame: Baseline, Week 24
  9. Change From Baseline in the Physical Component Summary Scale (PCS-12) at Week 24Time frame: Baseline, Week 24
  10. Change From Baseline in the Mental Component Summary Scale (MCS-12) at Week 24Time frame: Baseline, Week 24
  11. Annualized Event Rate of All Major Clinical Events Pre- and Post-Treatment With UX007Time frame: 18 months before and after UX007 initiation
  12. Annualized Duration Rate of All Major Clinical Events Pre- and Post-Treatment With UX007Time frame: 18 months before and after UX007 initiation
  13. Annualized Event Rate of Major Rhabdomyolysis Clinical Events Pre- and Post-Treatment With UX007Time frame: 18 months before and after UX007 initiation
  14. Annualized Duration Rate of Major Rhabdomyolysis Clinical Events Pre- and Post-Treatment With UX007Time frame: 18 months before and after UX007 initiation
  15. Annualized Event Rate of Major Hypoglycemia Clinical Events Pre- and Post-Treatment With UX007Time frame: 18 months before and after UX007 initiation
  16. Annualized Duration Rate of Major Hypoglycemia Clinical Events Pre- and Post-Treatment With UX007Time frame: 18 months before and after UX007 initiation
  17. Annualized Event Rate of Major Cardiac Clinical Events Pre- and Post-Treatment With UX007Time frame: 18 months before and after UX007 initiation
  18. Annualized Duration Rate of Major Cardiac Clinical Events Pre- and Post-Treatment With UX007Time frame: 18 months before and after UX007 initiation

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • University of Southern Florida

    Tampa, Florida

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Boston Children's Hospital

    Boston, Massachusetts

  • Children's Hospital of Pittsburgh of UPMC

    Pittsburgh, Pennsylvania

  • Vanderbilt Medical Center

    Nashville, Tennessee

  • University of Utah

    Salt Lake City, Utah

  • Birmingham Children's Hospital

    Birmingham, United Kingdom

  • National Hospital for Neurology and Neurosurgery

    London, United Kingdom

  • Great Ormond Street Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.